{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Pleural spread or recurrence of thymic epithelial tumors (TETs) is a tricky puzzle in the clinic and there is currently no recognized effective treatment."
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 1,
        "evidence": "enrolled 45 patients receiving S-HITOC"
      },
      "Intervention": {
        "score": 2,
        "evidence": "receiving S-HITOC with 25\u2009mg/m 2 doxorubicin and 50\u2009mg/m 2 cisplatin"
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial evaluated the safety and efficacy of cytoreductive surgery and hyperthermic intrathoracic chemotherapy (S-HITOC) for TETs with pleural spread or recurrence."
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "enrolled 45 patients receiving S-HITOC"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The estimated 2-year PFS and OS rates were 82.8% and 100.0%, respectively."
      },
      "Harms": {
        "score": 1,
        "evidence": "Treatment-related adverse events of grade \u22653 occurred in eight (17.8%) patients."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial number: NCT05446935"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 9,
    "max_score": 25
  },
  "model": "gpt-4o"
}